SGP vs TLSI
SGP: Spyglass Pharma is a clinical-stage biotech developing an innovative sustained-release drug delivery platform to improve patient outcomes in cataract surgery. TLSI: TriSalus is a medical technology company integrating proprietary pressure-enabled drug delivery devices with immunotherapeutics to improve outcomes for patients with liver and pancreatic cancer.
Side-by-side fundamentals
| Metric | SGP | TLSI | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $20.82 | $4.32 | |
| Market cap as of 2026-07-30 | $696M | $265M | |
| PEG as of 2026-07-30 | n/a | -0.12 | |
| Net margin as of 2026-07-30 | n/a | -60.9% | |
| Gross margin as of 2026-07-30 | n/a | +85.1% | |
| Operating margin as of 2026-07-30 | n/a | -62.5% | |
| ROE as of 2026-07-30 | -75.4% | +12.0% | TLSI higher |
| ROA as of 2026-07-30 | -68.8% | -59.4% | TLSI higher |
| Debt / equity as of 2026-07-30 | 0.00 | 2.58 | SGP lower |
| Revenue growth (YoY) as of 2026-07-30 | n/a | +39.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +53.9% | |
| Beta as of 2026-07-30 | 0.91 | 0.40 | |
| 1-year return as of 2026-07-27 close | n/a | -5.3% |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.